Kailera Therapeutics raised $400M in a series A funding round co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments to advance its portfolio of obesity drugs.
Kailera Therapeutics raised $400M in a series A funding round co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments to advance its portfolio of obesity drugs.
10/01/24, 1:33 PM
Location
bostonMoney raised
$400 million
Industry
biotechnology
health care
Round Type
series a
Investors
Lyra Capital, Rtw Investments, Bain Capital Life Sciences, Atlas Venture
Kailera Therapeutics has launched with a significant backing of $400 million in series A funding to support its entry into the obesity market with acquired assets from China. The funding will help advance its innovative therapies that aim to improve quality of life and health for individuals struggling with obesity.
Company Info
Location
boston, massachusetts, united states
Additional Info
Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA.